fda approves tas-102, nivolumab breakthrough in rcc, two priority reviews, and more
Published 8 years ago • 397 plays • Length 6:56Download video MP4
Download video MP3
Similar videos
-
1:34
fda approves frontline nivolumab for advanced melanoma
-
3:04
fda approves nivolumab plus cabozantinib for advanced renal cell carcinoma
-
4:43
nivolumab in renal cell carcinoma
-
6:52
nivolumab in renal cell carcinoma
-
0:37
dr. petrylak on fda approval of nivolumab in bladder cancer
-
11:42
nivolumab in renal cell carcinoma
-
0:29
dr. mckay on fda approval of frontline cabozantinib in rcc
-
0:41
dr. toni choueiri on cabozantinib and nivolumab combination in kidney cancer
-
1:22
copy of dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
4:58
tas-102 in refractory metastatic colorectal cancer
-
4:54
the first oral fluoropyrimidine for mcrc—tas-102
-
0:57
fda approves cabozantinib for advanced rcc
-
1:40
dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
-
2:36
kidney cancer research: fda approves immunotherapy combination
-
1:36
liquid biopsies and tumor-informed ctdna profiling in metastatic urothelial carcinoma
-
2:59
pivot io 009 trial
-
1:42
dr. overman on the impact of nivolumab in mcrc
-
1:10
robert filgin md provides an update on nivolumab (opdivo) in rcc
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc